Literature DB >> 35351656

FOSL1 promotes proneural-to-mesenchymal transition of glioblastoma stem cells via UBC9/CYLD/NF-κB axis.

Zhengxin Chen1, Shuai Wang2, Hai-Lin Li3, Hui Luo3, Xiaoting Wu4, Jiacheng Lu3, Hong-Wei Wang5, Yuanyuan Chen6, Dan Chen7, Wen-Ting Wu8, Shuyu Zhang9, Qiongqiong He10, Daru Lu11, Ning Liu3, Yongping You1, Wei Wu12, Huibo Wang13.   

Abstract

Proneural (PN) to mesenchymal (MES) transition (PMT) is a crucial phenotypic shift in glioblastoma stem cells (GSCs). However, the mechanisms driving this process remain poorly understood. Here, we report that Fos-like antigen 1 (FOSL1), a component of AP1 transcription factor complexes, is a key player in regulating PMT. FOSL1 is predominantly expressed in the MES subtype, but not PN subtype, of GSCs. Knocking down FOSL1 expression in MES GSCs leads to the loss of MES features and tumor-initiating ability, whereas ectopic expression of FOSL1 in PN GSCs is able to induce PMT and maintain MES features. Moreover, FOSL1 facilitates ionizing radiation (IR)-induced PMT and radioresistance of PN GSCs. Inhibition of FOSL1 enhances the anti-tumor effects of IR by preventing IR-induced PMT. Mechanistically, we find that FOSL1 promotes UBC9-dependent CYLD SUMOylation, thereby inducing K63-linked polyubiquitination of major nuclear factor κB (NF-κB) intermediaries and subsequent NF-κB activation, which results in PMT induction in GSCs. Our study underscores the importance of FOSL1 in the regulation of PMT and suggests that therapeutic targeting of FOSL1 holds promise to attenuate molecular subtype switching in patients with glioblastomas.
Copyright © 2022 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FOSL1; UBC9/CYLD/NF-κB axis; glioblastoma stem cells; proneural-to-mesenchymal transition

Mesh:

Substances:

Year:  2022        PMID: 35351656      PMCID: PMC9263249          DOI: 10.1016/j.ymthe.2021.10.028

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  47 in total

Review 1.  Putative role of SUMOylation in controlling the activity of deubiquitinating enzymes in cancer.

Authors:  Katarzyna C Masoumi; Gemma Marfany; Yingli Wu; Ramin Massoumi
Journal:  Future Oncol       Date:  2016-01-18       Impact factor: 3.404

2.  The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.

Authors:  K Maurus; A Hufnagel; F Geiger; S Graf; C Berking; A Heinemann; A Paschen; S Kneitz; C Stigloher; E Geissinger; C Otto; A Bosserhoff; M Schartl; S Meierjohann
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

3.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Authors:  Qianghu Wang; Baoli Hu; Xin Hu; Hoon Kim; Massimo Squatrito; Lisa Scarpace; Ana C deCarvalho; Sali Lyu; Pengping Li; Yan Li; Floris Barthel; Hee Jin Cho; Yu-Hsi Lin; Nikunj Satani; Emmanuel Martinez-Ledesma; Siyuan Zheng; Edward Chang; Charles-Etienne Gabriel Sauvé; Adriana Olar; Zheng D Lan; Gaetano Finocchiaro; Joanna J Phillips; Mitchel S Berger; Konrad R Gabrusiewicz; Guocan Wang; Eskil Eskilsson; Jian Hu; Tom Mikkelsen; Ronald A DePinho; Florian Muller; Amy B Heimberger; Erik P Sulman; Do-Hyun Nam; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

Review 4.  Deubiquitinases in the regulation of NF-κB signaling.

Authors:  Edward W Harhaj; Vishva M Dixit
Journal:  Cell Res       Date:  2010-11-30       Impact factor: 25.617

5.  USP9X deubiquitinates ALDH1A3 and maintains mesenchymal identity in glioblastoma stem cells.

Authors:  Zhengxin Chen; Hong-Wei Wang; Shuai Wang; Ligang Fan; Shuang Feng; Xiaomin Cai; Chenghao Peng; Xiaoting Wu; Jiacheng Lu; Dan Chen; Yuanyuan Chen; Wenting Wu; Daru Lu; Ning Liu; Yongping You; Huibo Wang
Journal:  J Clin Invest       Date:  2019-04-08       Impact factor: 14.808

6.  FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.

Authors:  Peng Cheng; Jia Wang; Indrayani Waghmare; Stefania Sartini; Vito Coviello; Zhuo Zhang; Sung-Hak Kim; Ahmed Mohyeldin; Marat S Pavlyukov; Mutsuko Minata; Claudia L L Valentim; Rishi Raj Chhipa; Krishna P L Bhat; Biplab Dasgupta; Concettina La Motta; Madhuri Kango-Singh; Ichiro Nakano
Journal:  Cancer Res       Date:  2016-08-28       Impact factor: 12.701

7.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression.

Authors:  L Bakiri; S Macho-Maschler; I Custic; J Niemiec; A Guío-Carrión; S C Hasenfuss; A Eger; M Müller; H Beug; E F Wagner
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

9.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation.

Authors:  Mutsuko Minata; Alessandra Audia; Junfeng Shi; Songjian Lu; Joshua Bernstock; Marat S Pavlyukov; Arvid Das; Sung-Hak Kim; Yong Jae Shin; Yeri Lee; Harim Koo; Kirti Snigdha; Indrayani Waghmare; Xing Guo; Ahmed Mohyeldin; Daniel Gallego-Perez; Jia Wang; Dongquan Chen; Peng Cheng; Farah Mukheef; Minerva Contreras; Joel F Reyes; Brian Vaillant; Erik P Sulman; Shi-Yuan Cheng; James M Markert; Bakhos A Tannous; Xinghua Lu; Madhuri Kango-Singh; L James Lee; Do-Hyun Nam; Ichiro Nakano; Krishna P Bhat
Journal:  Cell Rep       Date:  2019-02-12       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.